| Literature DB >> 34130596 |
Mariana Brütt Pacheco1, Vânia Camilo1, Rui Henrique1,2,3, Carmen Jerónimo1,3.
Abstract
Epigenome editing consists of fusing a predesigned DNA recognition unit to the catalytic domain of a chromatin modifying enzyme leading to the introduction or removal of an epigenetic mark at a specific locus. These platforms enabled the study of the mechanisms and roles of epigenetic changes in several research domains such as those addressing pathogenesis and progression of cancer. Despite the continued efforts required to overcome some limitations, which include specificity, off-target effects, efficacy, and longevity, these tools have been rapidly progressing and improving.Since prostate cancer is characterized by multiple genetic and epigenetic alterations that affect different signalling pathways, epigenetic editing constitutes a promising strategy to hamper cancer progression. Therefore, by modulating chromatin structure through epigenome editing, its conformation might be better understood and events that drive prostate carcinogenesis might be further unveiled.This review describes the different epigenome engineering tools, their mechanisms concerning gene's expression and regulation, highlighting the challenges and opportunities concerning prostate cancer research.Entities:
Keywords: Prostate cancer; crispr-dCas9; epigenome editing; fusion proteins
Mesh:
Substances:
Year: 2021 PMID: 34130596 PMCID: PMC9067534 DOI: 10.1080/15592294.2021.1939477
Source DB: PubMed Journal: Epigenetics ISSN: 1559-2294 Impact factor: 4.861